Loading...
•
Dec 31, 2025
Telix Pharmaceuticals Q4 2025 Earnings Report
Key Takeaways
Telix Pharmaceuticals achieved double-digit revenue growth and positive adjusted operating cash flow in FY 2025, with revenue reaching US$803.8 million, a 56% increase year-over-year. The company invested significantly in R&D and strategic acquisitions, resulting in a non-material loss before tax of US$5.3 million, while maintaining a year-end cash balance of US$141.9 million.
Revenue increased by 56% year-over-year to US$803.8 million, exceeding full-year guidance.
Adjusted EBITDA was US$39.5 million, reflecting increased operating expenditure due to strategic investments.
A non-material loss before tax of US$5.3 million was reported, including significant non-cash finance costs and increased asset amortization.
The year-end cash balance stood at US$141.9 million after US$246.4 million in strategic investments and a final contingent consideration payment of US$51.8 million.
Revenue by Segment
Forward Guidance
Telix Pharmaceuticals provided FY 2026 Group Revenue guidance of US$950 million to US$970 million, reflecting continued growth in product sales and a full year of RLS revenue contribution. Pipeline R&D expenditure is guided to be between US$200 million and US$240 million.
Positive Outlook
- Anticipated revenue growth of 18% to 21% in FY 2026.
- Continued momentum in the core cash-generative Precision Medicine franchise.
- Reinvestment of earnings to accelerate the therapeutic pipeline, including three pivotal stage trials.
- Expansion of the Precision Medicine growth opportunity through label expansion studies and new product launches.
- Full year revenue contribution from RLS is expected to bolster overall revenue.
Challenges Ahead
- Increased R&D expenditure guidance of US$200 million to US$240 million, indicating continued high investment.
- No specific negative guidance points were explicitly stated in the provided text, but high investment could impact short-term profitability.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...